Skip to main content
. Author manuscript; available in PMC: 2014 Aug 15.
Published in final edited form as: Clin Cancer Res. 2013 Jul 5;19(16):4532–4540. doi: 10.1158/1078-0432.CCR-13-0657

Figure. 1.

Figure. 1

Characterization of BRAF mutations in NSCLC A. In vitro kinase assay. Flag-tagged wild type (WT) or mutant BRAF protein was immunoprecipitated with anti-FLAG antibody and subjected to in vitro kinase assays in the presence of ATP and recombinant MEK. Immunoblotting was used to detect indicated proteins. B. Expression of activated MEK and ERK1/2 in NIH-3T3 cells expressing either WT or mutant BRAF. Immunoblotting was used to detect indicated proteins. C. Cells from B. were grown in soft agar and colonies were assayed 3 weeks after plating. The mean (and SD) colony numbers are plotted.